

Procainamide Hydrochloride Injection, USP

ISSUED 07/17/98

-----  
1. CHEMICAL PRODUCT AND COMPANY IDENTIFICATION  
-----

MATERIAL NAME: Procainamide Hydrochloride Injection, USP  
List Number: 1826, 1902, 1903

MANUFACTURER: Hospital Products Division  
Abbott Laboratories  
Abbott Park, Illinois 60064

EMERGENCY TELEPHONE NUMBER: 1-847-937-7970  
CHEMTREC TELEPHONE NUMBER: 1-800-424-9300

2. COMPOSITION/INFORMATION ON INGREDIENTS  
-----

INGREDIENT NAME: Procainamide Hydrochloride \*  
CAS/RTECS NUMBERS: 612-39-1/CV2295000  
OSHA-PEL 8HR TWA: N/L  
STEL: N/L  
CEILING: N/L  
ACGIH-TLV 8HR TWA: N/L  
STEL: N/L  
CEILING: N/L  
OTHER 8HR TWA: 1 mg/m3 for procainamide (Abbott Laboratories)  
LIMITS STEL: 3 mg/m3  
CEILING: N/A

\* Hazardous per OSHA criteria

3. HAZARDS INFORMATION  
-----

EMERGENCY OVERVIEW: In clinical use, this material is used to control arrhythmias. Target organs include the heart, hematopoietic system, immune system and possibly the skin.

ROUTE(S) OF ENTRY: Skin: Unlikely  
Inhalation: Unlikely  
Ingestion: Unlikely

INGESTION RATING: N/D

Procainamide Hydrochloride Injection, USP

ISSUED 07/17/98

## 3. HAZARDS INFORMATION, continued

-----  
SKIN ABSORPTION RATING: N/D

INHALATION RATING: N/D

CORROSIVENESS RATING: N/D

SKIN CONTACT RATING: N/D

SKIN SENSITIZATION RATING: N/D

EYE CONTACT RATING: N/D

TARGET ORGANS: Heart, hematopoietic system, immune system, possibly  
skin

CARCINOGENICITY RATING: NTP: N/L IARC: N/L OSHA: N/L

ACGIH: N/L

None

SIGNS AND SYMPTOMS: N/D. In clinical use, procainamide can produce alterations in cardiac conductivity, tachycardia, cardiac blockage, allergic reactions like dermatitis or asthma, lupus erythematosus-like syndrome, agranulocytosis, anemia, leukopenia, bone marrow depression, depression, dizziness, giddiness, and fever, among others.

MEDICAL CONDITIONS AGGRAVATED BY EXPOSURE: N/D. Sensitivity to procainamide, procaine and similar drugs; lupus; Torsade de Pointes; congestive heart function; renal insufficiency; myasthenia gravis; digitalis therapy, and blood diseases.

## 4. FIRST AID MEASURES

-----  
EYES: Remove from source of exposure. Flush with copious amounts of water. If irritation persists or signs of toxicity occur, seek medical attention. No known antidote. Provide symptomatic/supportive care, monitoring cardiac, hematopoietic and vital functions, as necessary.

Procainamide Hydrochloride Injection, USP

ISSUED 07/17/98

## 4. FIRST AID MEASURES, continued

SKIN: Remove from source of exposure. Flush with copious amounts of water. If irritation persists or signs of toxicity occur, seek medical attention. No known antidote. Provide symptomatic/supportive care, monitoring cardiac, hematopoietic and vital functions, as necessary.

INGESTION: Remove from source of exposure. If signs of toxicity occur, seek medical attention. No known antidote. Provide symptomatic/supportive care, monitoring cardiac, hematopoietic and vital functions, as necessary.

INHALATION: Remove from source of exposure. If signs of toxicity occur, seek medical attention. No known antidote. Provide symptomatic/supportive care, monitoring cardiac, hematopoietic and vital functions, as necessary.

## 5. FIRE FIGHTING PROCEDURES

FLASH POINT: Non-flammable

FLASH POINT METHOD: N/A

LOWER EXPLOSIVE LIMIT(%): N/D

UPPER EXPLOSIVE LIMIT(%): N/D

AUTOIGNITION TEMPERATURE: N/D

FIRE & EXPLOSION HAZARDS: None

EXTINGUISHING MEDIA: Use media appropriate for primary cause of fire.

FIRE FIGHTING INSTRUCTIONS: None

## 6. ACCIDENTAL RELEASE MEASURES

SPILL OR RELEASE PROCEDURES: Absorb with suitable material, flush with water.

ISSUED 07/17/98

-----

7. HANDLING AND STORAGE

-----

HANDLING: No special handling required.

STORAGE: Store at controlled room temperature of 15-30 degrees C (59-86 degrees F).

SPECIAL PRECAUTIONS: N/D.

8. EXPOSURE CONTROLS/PERSONAL PROTECTION

-----

ENGINEERING CONTROLS: No special provisions are required under normal product use conditions.

RESPIRATORY PROTECTION: Respiratory protection is not needed during normal product use.

SKIN PROTECTION: If skin contact is likely, neoprene or vinyl rubber gloves are recommended.

EYE PROTECTION: Eye protection is not required during typical product use conditions. Eye protection is recommended if eye contact is likely.

OTHER PROTECTION: N/A

9. PHYSICAL AND CHEMICAL PROPERTIES

-----

APPEARANCE/PHYSICAL STATE: Clear liquid

ODOR: N/A

BOILING POINT: Water (approx.)

MELTING/FREEZING POINT: Water (approx.)

VAPOR PRESSURE (mm Hg): N/A

VAPOR DENSITY (Air=1): N/A

EVAPORATION RATE: N/A

BULK DENSITY: N/D

SPECIFIC GRAVITY: 1.0183 - 1.0893

SOLUBILITY: Aqueous solution

pH: 4.0 - 6.0

-----  
9. PHYSICAL AND CHEMICAL PROPERTIES, continued  
-----

VISCOSITY: 1.335 - 7.96 centipoise

10. STABILITY AND REACTIVITY  
-----

CHEMICAL STABILITY: No conditions to avoid.

INCOMPATIBILITIES: N/D.

HAZARDOUS DECOMPOSITION PRODUCTS: When heated to decomposition, it emits toxic fumes of NOx.

HAZARDOUS POLYMERIZATION: N/D.

11. TOXICOLOGICAL INFORMATION  
-----

ORAL TOXICITY: N/D. LD50 = 1110 > 2000 mg/kg in mice and rats for procainamide hydrochloride.

DERMAL TOXICITY: N/D

INHALATION TOXICITY: N/D

CORROSIVENESS: N/D

DERMAL IRRITATION: N/D

OCULAR IRRITATION: N/D

DERMAL SENSITIZATION: N/D. Can produce cross reactivity in persons allergic to ester-type local anesthetics.

SPECIAL TARGET ORGAN EFFECTS: N/D. Procainamide is an antiarrhythmic drug. It is cardiotoxic (can cause cardiac blockage), can produce a lupus erythematosus-like syndrome and can injure the hematopoietic system.

CARCINOGENICITY INFORMATION: N/D

-----  
12. ECOLOGICAL INFORMATION  
-----

ECOLOGICAL INFORMATION: N/D

13. DISPOSAL CONSIDERATIONS  
-----

WASTE DISPOSAL METHODS: Dispose of in accordance with local, state and federal regulations.

14. TRANSPORTATION INFORMATION  
-----

DOT STATUS: Not Regulated  
PROPER SHIPPING NAME: N/A  
HAZARD CLASS: N/A  
UN NUMBER: N/A  
PACKING GROUP: N/A  
REPORTABLE QUANTITY: N/A

IATA/ICAO STATUS: Not Regulated  
PROPER SHIPPING NAME: N/A  
HAZARD CLASS: N/A  
UN NUMBER: N/A  
PACKING GROUP: N/A  
REPORTABLE QUANTITY: N/A

IMO STATUS: Not Regulated  
PROPER SHIPPING NAME: N/A  
HAZARD CLASS: N/A  
UN NUMBER: N/A  
PACKING GROUP: N/A  
REPORTABLE QUANTITY: N/A  
FLASH POINT: Non-flammable

15. REGULATORY INFORMATION  
-----

TSCA STATUS: N/A

CERCLA STATUS: N/L

Procainamide Hydrochloride Injection, USP

ISSUED 07/17/98

-----  
15. REGULATORY INFORMATION, continued  
-----

SARA STATUS: N/L

RCRA STATUS: N/L

PROP 65 (CA): N/L

16. OTHER INFORMATION  
-----

LEGEND: N/A = Not Applicable  
N/D = Not Determined  
N/L = Not Listed  
L = Listed  
C = Ceiling  
S = Short-term  
(R) = Registered Trademark of Abbott Laboratories  
(TM) = Registered Trademark of Abbott Laboratories

The information and recommendations contained herein are based upon information believed to be reliable. However, Abbott Laboratories does not guarantee their accuracy or completeness NOR SHALL ANY OF THIS INFORMATION CONSTITUTE A WARRANTY, WHETHER EXPRESSED OR IMPLIED, AS TO THE SAFETY OF THE GOODS, THE MERCHANTABILITY OF THE GOODS, OR THE FITNESS OF THE GOODS FOR A PARTICULAR PURPOSE. Adjustment to conform with actual conditions of usage may be required. Abbott Laboratories assumes no responsibility for results obtained or for incidental or consequential damages arising from the use of these data. No freedom from infringement of any patent, copyright or trademark is to be inferred.

APPROVED BY: DLF